Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 15;119(14):2390-2404.
doi: 10.1093/cvr/cvad088.

Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function

Michele Ciccarelli  1 , Inês Falcão Pires  2 , Johann Bauersachs  3 , Luc Bertrand  4 , Christophe Beauloye  4 , Dana Dawson  5 , Nazha Hamdani  6   7 , Denise Hilfiker-Kleiner  8 , Linda W van Laake  9 , Frank Lezoualc'h  10 , Wolfgang A Linke  11 , Ida G Lunde  12 , Peter P Rainer  13   14 , Antonella Rispoli  1 , Valeria Visco  1 , Albino Carrizzo  1   15 , Matteo Dal Ferro  16   17 , Davide Stolfo  16   18 , Jolanda van der Velden  19 , Serena Zacchigna  17   20 , Stephane Heymans  21 , Thomas Thum  22   23 , Carlo Gabriele Tocchetti  24
Affiliations
Free article

Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function

Michele Ciccarelli et al. Cardiovasc Res. .
Free article

Abstract

While chronic heart failure (CHF) treatment has considerably improved patient prognosis and survival, the therapeutic management of acute heart failure (AHF) has remained virtually unchanged in the last decades. This is partly due to the scarcity of pre-clinical models for the pathophysiological assessment and, consequently, the limited knowledge of molecular mechanisms involved in the different AHF phenotypes. This scientific statement outlines the different trajectories from acute to CHF originating from the interaction between aetiology, genetic and environmental factors, and comorbidities. Furthermore, we discuss the potential molecular targets capable of unveiling new therapeutic perspectives to improve the outcome of the acute phase and counteracting the evolution towards CHF.

Keywords: Acute heart failure; New strategies; Phenotypes; Pre-clinical models; Scientific statement; Therapeutic management; Trajectories.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T.T. received speaker fees and/or holds advisory board seats from Böhringer Ingelheim, Sanofi-Genzyme, Takeda, Novo-Nordisk, Amicus Therapeutics, KSILINK not related to the present article. T.T. filed and licensed patents about non-coding RNAs, and he is founder and shareholder of Cardior Pharmaceuticals (not related to this article). P.R. received travel support, speaker fees, honoraria from Novartis, Vifor, Böhringer, and Daiichi Sankyo (not related to this article). L.W.V.L. received Consultancy fees to UMCU from Abbott, Medtronic, Vifor, Novartis (not related to the present article). W.L. received honoraria from Bristol-Myers Squibb (MyoKardia), Merck, Sharp& Dohme (MSD, USA), and Servier, as well as a research grant from MSD (not related to the present article). J.B. received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Corvia, not related to the present article; and research support for the department from Zoll, CVRx, Abiomed, not related to the present article. C.G.T. reports Receipt of honoraria or consultation fees: VivaLyfe, Univers Formazione, Solaris, Myocardial Solutions; and is listed as an inventor of 2 patents related to HF. All other authors have nothing to disclose.

Publication types